Citadel Advisors’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $141K | Sell |
35,166
-144,849
| -80% | -$579K | ﹤0.01% | 5137 |
|
|
2025
Q1 | $164K | Sell |
180,015
-436,894
| -71% | -$398K | ﹤0.01% | 4957 |
|
|
2024
Q4 | $1.71M | Buy |
616,909
+567,349
| +1,145% | +$1.57M | ﹤0.01% | 2764 |
|
|
2024
Q3 | $259K | Buy |
49,560
+23,665
| +91% | +$124K | ﹤0.01% | 4403 |
|
|
2024
Q2 | $115K | Sell |
25,895
-66,823
| -72% | -$298K | ﹤0.01% | 4895 |
|
|
2024
Q1 | $710K | Sell |
92,718
-66,745
| -42% | -$511K | ﹤0.01% | 3538 |
|
|
2023
Q4 | $679K | Buy |
159,463
+25,453
| +19% | +$108K | ﹤0.01% | 3412 |
|
|
2023
Q3 | $563K | Sell |
134,010
-11,590
| -8% | -$48.7K | ﹤0.01% | 3625 |
|
|
2023
Q2 | $811K | Sell |
145,600
-648,223
| -82% | -$3.61M | ﹤0.01% | 3184 |
|
|
2023
Q1 | $4.55M | Buy |
+793,823
| New | +$4.55M | ﹤0.01% | 1891 |
|
|
2022
Q4 | – | Sell |
-110,648
| Closed | -$297K | – | 6376 |
|
|
2022
Q3 | $297K | Sell |
110,648
-10,179
| -8% | -$27.3K | ﹤0.01% | 4550 |
|
|
2022
Q2 | $577K | Buy |
120,827
+22,530
| +23% | +$108K | ﹤0.01% | 3990 |
|
|
2022
Q1 | $402K | Sell |
98,297
-8,681
| -8% | -$35.5K | ﹤0.01% | 4655 |
|
|
2021
Q4 | $729K | Buy |
106,978
+12,512
| +13% | +$85.3K | ﹤0.01% | 4195 |
|
|
2021
Q3 | $1.1M | Sell |
94,466
-76,600
| -45% | -$888K | ﹤0.01% | 3665 |
|
|
2021
Q2 | $2.92M | Sell |
171,066
-69,335
| -29% | -$1.18M | ﹤0.01% | 2785 |
|
|
2021
Q1 | $4.76M | Sell |
240,401
-12,141
| -5% | -$240K | ﹤0.01% | 2161 |
|
|
2020
Q4 | $5.21M | Buy |
252,542
+11,464
| +5% | +$237K | ﹤0.01% | 1730 |
|
|
2020
Q3 | $6.34M | Buy |
+241,078
| New | +$6.34M | ﹤0.01% | 1361 |
|